Sai Life Sciences completes Phase II of production block 11 at Bidar
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Terufusion Advanced Infusion Systems combine a smart syringe pump, smart infusion pump, and pump monitoring system software for precise and efficient drug administration
The company is bringing precision therapies for gynaecological cancers
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Rivaroxaban is used to treat venous thromboembolism
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Subscribe To Our Newsletter & Stay Updated